T1	p 92 114	stable COPD patients .
T2	p 126 142	In COPD patients
T3	p 589 622	days , 60 COPD patients underwent
T4	i 613 771	underwent dyspnea evaluation ( VAS score ) and pulmonary function testing at baseline and one hour after placebo or 300?g indacaterol administration . RESULTS
T5	o 54 88	specific airway resistance changes
T6	o 457 513	that specific airway resistance changes ( ?sRAW ) should
T7	o 613 686	underwent dyspnea evaluation ( VAS score ) and pulmonary function testing
T8	o 764 820	RESULTS Spirographic and ?sRAW-based criteria identified
T9	o 856 887	respectively . ?sRAW correlated
T10	o 893 947	changes of intrathoracic gas volume ( ?ITGV ) ( r=0.61
T11	o 960 987	) , residual volume ( ?RV )
T12	o 1011 1019	, ?FVC (
T13	o 1041 1049	and ?VAS
T14	o 1075 1112	while ?FEV1 correlated only with ?FVC
T15	o 1172 1205	?ITGV ( p=0.002 ) , ?RV ( p=0.023
T16	o 1214 1224	?VAS ( p <
T17	o 1275 1307	according to ?sRAW . CONCLUSIONS
T18	o 1370 1405	?sRAW-based criterion is preferable
T19	o 1409 1440	FEV1-FVC-based criteria , being
T20	o 1462 1503	to bronchodilator-induced improvements of